Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats

被引:33
作者
Ren, Binhui [1 ]
Shen, Yi [1 ]
Shao, Hongtao [1 ]
Qian, Jianjun [1 ]
Wu, Haiwei [1 ]
Jing, Hua [1 ]
机构
[1] Nanjing Univ, Sch Clin Med, Jinling Hosp, Dept Thorac & Cardiovasc Surg, Nanjing 210002, Peoples R China
关键词
B-type natriuretic peptide; ischemia-reperfusion injury; infarct size;
D O I
10.1016/j.cca.2006.08.027
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Brain natriuretic peptide (BNP) has recently been shown to have a cardioprotective effect in animal models of myocardial ischemia-reperfusion (I-R) injury. We hypothesized that exogenous BNP limits myocardial infarction on nitric oxide synthase pathway. Methods: A rat model of myocardial I-R injury was established by ligating the left descending coronary artery for 30 min and then reperfusing for 2 h. BNP was injected with different dose 5 min after the ligation and lasting for 145 min. The myocardial infarct size and the area at risk of ischemia were measured by staining with triphenyltetrazolium chloride (TTC) and Evans blue dye. To examine the role of nitric oxide synthase (NOS), expression of eNOS in the left ventricle was analyzed by western blotting. N-omega-nitro-L-arginine methyl ester (L-NAME; 30 ug/kg), or S-methylisothiourea (SMT; 3 ug/kg) was administrated before l-R with or without BNP. Results: The control infarct-to-risk ratio was 45.1 +/- 1.72% (means SE). BNP infused 5 min after ischemia limited infarct size in a dosage-dependent manner, with maximal protection observed at 0.01 ug/(kg min) (intarct-to-risk: 24.7 +/- 1.69%, P < 0.0 1 vs. control), associated with a 10-fold increase of myocardial endothelial nitric oxide synthase above the control value. Protection afforded by BNP was abolished by L-NAME but not by SMT, suggesting the involvement of putative endothelial but not inducible nitric oxide synthase activation. Conclusions: We conclude that natriuretic peptide/NOS/NO signaling may constitute an important injury-limiting mechanism in myocardium. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 22 条
  • [1] Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use
    Boomsma, F
    van den Meiracker, AH
    [J]. CARDIOVASCULAR RESEARCH, 2001, 51 (03) : 442 - 449
  • [2] D'Souza S. P., 2003, British Journal of Pharmacology, V138, p21P
  • [3] B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening
    D'Souza, SP
    Yellon, DM
    Martin, C
    Schulz, R
    Heusch, G
    Onody, A
    Ferdinandy, P
    Baxter, GF
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 284 (05): : H1592 - H1600
  • [4] Role of nitric oxide in myocardial preconditioning
    Dawn, B
    Bolli, R
    [J]. NITRIC OXIDE: NOVEL ACTIONS, DELETERIOUS EFFECTS AND CLINICAL POTENTIAL, 2002, 962 : 18 - 41
  • [5] Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart:: a study in endothelial NO synthase knockout mice
    Flögel, U
    Decking, UKM
    Gödecke, A
    Schrader, J
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (04) : 827 - 836
  • [6] PKC-δ inhibition does not block preconditioning-induced preservation in mitochondrial ATP synthesis and infarct size reduction in rats
    Fryer, RM
    Hsu, AK
    Wang, YG
    Henry, M
    Eells, J
    Gross, GJ
    [J]. BASIC RESEARCH IN CARDIOLOGY, 2002, 97 (01) : 47 - 54
  • [7] Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion
    Gourine, AV
    Gonon, AT
    Pernow, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 280 (03): : H1105 - H1112
  • [8] BIOLOGICAL CHARACTERIZATION OF HUMAN BRAIN NATRIURETIC PEPTIDE (BNP) AND RAT BNP - SPECIES-SPECIFIC ACTIONS OF BNP
    KAMBAYASHI, Y
    NAKAO, K
    KIMURA, H
    KAWABATA, T
    NAKAMURA, M
    INOUYE, K
    YOSHIDA, N
    IMURA, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (02) : 599 - 605
  • [9] Lucas KA, 2000, PHARMACOL REV, V52, P375
  • [10] MONCADA S, 1991, PHARMACOL REV, V43, P109